CTI BioPharma - Articles and news items

Tosedostat in combination with low dose cytarabine achieves primary endpoint in Phase 2 study

Industry news / 15 June 2015 / Victoria White

CTI BioPharma has announced findings from a Phase 2 trial of tosedostat in combination with low dose cytarabine in patients with acute myeloid leukaemia…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+